This page has been optimized for print.

FDA Approves Hologic's Adiana® Permanent Contraception System

Adiana system offers safe, simple, effective alternative to tubal ligation

BEDFORD, Mass. (July 7, 2009) /PRNewswire/ — Hologic, Inc., (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) has approved the Company's premarket approval (PMA) application for the Adiana® permanent contraception system. The Adiana system is designed to provide women a minimally-invasive, non-incision alternative to traditional, surgical means of permanent contraception. In January 2009, Hologic received CE marking approval for the Adiana system and commenced marketing and sales of this product in certain European countries.

The Adiana permanent contraception procedure is minimally invasive, requires no incisions and can be performed in the comfort of the doctor's office using local anesthesia. Patients are normally able to return to work or resume their daily activities within one day. In contrast, traditional methods of permanent contraception, such as tubal ligation, require more invasive surgical procedures, usually are conducted in a hospital under general anesthesia and typically require four to five days of recovery. As a result, these more invasive surgical procedures can pose serious risk of complications, including anesthesia-related problems and damage to organs or blood vessels. There were approximately 70,000 female transcervical contraception procedures performed in the U.S. last year.1

"While tubal ligation is the most common form of permanent contraception used throughout the world, hysteroscopic procedures such as those employing the Adiana permanent contraception system enable women to choose lifetime protection from pregnancy without the risks of general anesthesia and the longer recovery periods associated with traditional sterilization procedures," said Ted Anderson, M.D., Ph.D., associate professor of obstetrics and gynecology at Vanderbilt University, and clinical investigator of the pivotal clinical trial for the Adiana system. "The Adiana procedure is a safe and simple alternative that not only provides patients with peace of mind in preventing pregnancy, but also leaves nothing in the uterus that might limit women's options for future gynecologic tests and procedures."

The Adiana procedure is indicated for women who desire permanent birth control by occlusion of the fallopian tubes. Ideal candidates include women who do not want children in the future and would like the peace of mind and convenience of permanent birth control. The procedure may also be an ideal solution for women who desire permanent birth control but are poor candidates for surgery.

"Many women seek relief from the uncertainty and hassle of temporary birth control methods once they know their childbearing is complete. However, few know that permanent contraception is available without incisions, the use of general anesthesia, or need for lengthy hospital stays," said Tony Kingsley, senior vice president, GYN surgical products at Hologic. "With the Adiana permanent contraception system, we are very excited to be able to offer these women a new alternative for their long-term contraception needs."

During the Adiana procedure, a slender, flexible instrument is passed through the body's natural openings to deliver a low level of radiofrequency (RF) energy to a small section of each fallopian tube. A tiny, soft insert, about the size of a grain of rice, is then placed in each fallopian tube in the location where the energy was applied. During the three months following the procedure, the patient continues to use temporary birth control while new tissue grows in and around the Adiana inserts, eventually blocking the fallopian tubes. At three months, a special x-ray test (called a hysterosalpingogram or HSG) is performed to confirm the fallopian tubes are completely blocked and the patient may begin relying on Adiana for permanent contraception.

"This is another significant milestone for Hologic and our GYN surgical products business," said Tony Kingsley. "With FDA approval of the Adiana system, we are now able to provide physicians with another non-hormone, minimally-invasive therapy that addresses a significant issue for women in their post-childbearing years."

1 January 2009, "U.S. Markets for Women's Health Devices," iData Research, Vancouver, British Columbia, Canada. iData is an international market research and consulting group.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Forward Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the effect and adoption of the use of the Adiana system. There can be no assurance that the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Adiana system can only be determined on a case-by-case basis depending on the particular circumstances of the procedure and patient in question. Thus there can be no assurance of general adoption of this technology by the medical community. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic and Adiana are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Contact Information


For Investors:
Deborah R. Gordon
Vice President, Investor Relations
Hologic, Inc.
(781) 999-7716
For Media:
Stephanie Cilibrasi
Associate Product Manager, Adiana
Hologic, Inc.
(508) 263-8974